Showing 2471-2480 of 2530 results for "".
- Imprimis Announces Clinical Trial for Dropless TriMoxi Formulation in Canadahttps://modernod.com/news/imprimis-announces-clinical-trial-for-dropless-trimoxi-formulation-in-canada/2479968/Imprimis Pharmaceuticals announced that its Canadian partner, Advanced Dosage Forms, will begin enrolling patients at McGill University Health Centre (MUHC) for a clinical trial of Imprimis’s leading Dropless (triamcinolone acetonide-moxifloxacin) formulation aft
- Glaucoma Research Foundation Grant Leads to Breakthrough in Neuron Regenerationhttps://modernod.com/news/glaucoma-research-foundation-grant-leads-to-breakthrough-in-neuron-regeneration/2479971/The Glaucoma Research Foundation announced a team of neuroscience researchers, led by Adriana Di Polo, PhD, at the University of Montreal, have made a major breakthrough in the treatment of glaucoma. The research, which was made possible by a Glaucoma Research Foundation Shaffer Grant, could also
- Family Income, Ethnicity, and Health Literacy May Affect Children’s Vision, Eye Care Accesshttps://modernod.com/news/family-income-ethnicity-and-health-literacy-may-affect-childrens-vision-eye-care-access/2479982/August for many children in the United States is the beginning of a brand new school year. According to the recent report from the National Center for Children’s Vision and Eye H
- Surgeons from Vance Thompson Vision Make Impact with Mission Trip to Hondurashttps://modernod.com/news/surgeons-from-vance-thompson-vision-make-impact-with-mission-trip-to-honduras/2479985/This spring, Russell Swan, MD, led a team of surgeons from Vance Thompson Vision and the University of Iowa, plus staff members, on a mission trip to Honduras. Russell Swan, MD, John Berdahl, MD, Brandon Baartman, MD, and Dan Bettis, MD, were joined by five team members for a week-long sur
- EyeGate Announces FDA Approval of Two IDE Submissions for Ocular Bandage Gelhttps://modernod.com/news/eyegate-announces-fda-approval-of-two-ide-submissions-for-ocular-bandage-gel/2479995/EyeGate Pharmaceuticals announced the FDA has approved two of EyeGate’s investigational device exemption (IDE) applications for pilot studies of the company’s Ocular Bandage Gel (OBG) product for the acceleration of reepithelialization of large corneal epithelial defects in patients having underg
- Omeros Corporation Initiates Sales of Omidria in Europehttps://modernod.com/news/omeros-corporation-initiates-sales-of-omidria-in-europe/2479997/Omeros announced initial sales of »Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3% in Europe. Omidria, approved and commercially available in the United
- Heidelberg Engineering Announces Leadership Changeshttps://modernod.com/news/heidelberg-engineering-announces-leadership-changes/2480004/Heidelberg Engineering announced changes to the leadership team. Ali Tafreshi who has served in sales, marketing and research capacities in both the United States and German organizations
- Researchers Take Step Closer to Developing AMD Eye Dropshttps://modernod.com/news/researchers-take-step-closer-to-developing-amd-eye-drops/2480007/Scientists at the University of Birmingham, UK, say they are one step closer to developing an eye drop that could revolutionize treatment for age-related macular degeneration (AMD), according to a university news release. Scientists led by biochemist Felicity de Cogan, PhD, from the Univer
- FDA Releases Action Plan to Speed Up Market Entry for Biosimilarshttps://modernod.com/news/fda-releases-action-plan-to-speed-up-market-entry-for-biosimilars/2480010/The FDA unveiled plans Wednesday designed to facilitate the development, approval and market entry of biosimilars in the US. The Biosimilars Action Plan (BAP) “is aimed at promoting competition and affordability across the market for biologics and biosimilar products,” commented FDA C
- Bausch Health CEO: No Plans to Divest Bausch + Lombhttps://modernod.com/news/valeant-now-officially-bausch-health-companies-begins-trading-as-bhc/2480016/Valeant Pharmaceuticals International completed its name change to Bausch Health Companies. In an interview with Eyewire News to discuss the name change and direction of Bausch + Lomb, Bausch Health Chairman and CEO Joseph Papa said there are no plans to divest the eye care unit. “B